Eyebiotech Limited
https://eyebiotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eyebiotech Limited
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce
In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.
Merck & Co. To Enter Ophthalmology With EyeBio Buyout
Veteran developers stay on to accelerate development of potential first-in-class drug to challenge Bayer/Regeneron’s Eylea and Roche’s Vabysmo in a deal worth up to $3bn.
Europe’s Biotech Sector Still In Reasonable Shape
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice